Drug Profile
Stamulumab
Alternative Names: Anti-GDF-8 antibody; Anti-myostatin antibody; MYO 29; MYO-029Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology
- Developer Wyeth
- Class Monoclonal antibodies
- Mechanism of Action Myostatin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Muscular dystrophies; Sarcopenia
Most Recent Events
- 29 Oct 2007 Cambridge Antibody Technology has been integrated into MedImmune
- 22 Jun 2006 Cambridge Antibody Technology has been acquired by AstraZeneca
- 07 Feb 2005 Phase-I/II clinical trials in Muscular dystrophy in USA (IV)